RWF_KTE-C19-102

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-C19 in subjects with Relapsed/Refractory MCL.

Key Inclusion Criteria:

* Pathologically confirmed MCL

* Up to 5 prior regimens for MCL. Prior therapy must have included: Anthracycline or bendamustine-containing chemotherapy and Anti-CD20 monoclonal antibody therapy and Ibrutinib

* Relapsed or refractory disease, defined by the following: Disease progression after last regimen, or Refractory disease is defined failure to achieve a PR or CR to the last regimen

Key Exclusion Criteria:

* History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years

* History of allogeneic stem cell transplantation

* Prior CD19 targeted therapy
Phase II
NCT02601313
Oncology
Hematologic
John Godwin, M.D.
Kite Pharma, Inc
Laurie Delanty
  • Oncology and Hematology Care Eastside